What class of drugs does Margituximab/Meganex belong to?

Margetuximab is a new generation of targeted anti-HER2 monoclonal antibody and is regarded as a representative drug of the "anti-HER2 targeted antibody optimization platform". It also targets the HER2 protein like traditional HER2 monoclonal antibodies (such as trastuzumab), but its antibody structure has been engineered to enhance the binding ability of the Fc fragment to the immune system's receptors, thereby improving the killing efficiency of tumor cells. In the global trend of tumor immunotherapy, margituximab is often classified as an "Fc-engineered monoclonal antibody", which is an important feature that distinguishes it from traditional HER2 antibodies.

HER2 is a common tumor driver receptor that is significantly overexpressed in some breast cancers and gastric cancers. Traditional HER2-targeted drugs mainly exert inhibitory effects by blocking the receptor signaling pathway, while margetuximab is unique in that it also promotes the body's immune cells to attack tumor cells by enhancing antibody-dependent cellular cytotoxicity (ADCC). Multiple overseas data point out that the Fc region of margetuximab has been precisely designed so that it can bind to activating receptors more strongly and reduce the proportion of binding to inhibitory receptors, allowing the body's immune cells to more effectively fight against tumor cells.

Compared with other HER2-targeted drugs, margetuximab is positioned more as an "optimized immune antibody", not just blocking signaling pathways, but allowing the immune system to be more actively involved in treatment. This dual-mechanism model has led to an increasing trend in its use around the world, especially in some patients who have developed tolerance or reduced efficacy of previous HER2 treatments, and it provides a new treatment option.

Generally speaking, magituximab is an anti- HER2-targeted therapy and an engineered antibody biologic. It has new immune activation properties and is one of the systemic treatments for advanced or recurrent HER2-positive tumors.

Reference materials:https://www.margenza.com/